Item 7.01 Regulation FD Disclosure
On January 4, 2021, F-star Therapeutics, Inc. (the "Company") announced the
first patient dosed in its Phase 1 clinical trial evaluating FS222, a
potentially best-in-class bispecific antibody targeting CD137 and PD-L1. The
press release is attached hereto as Exhibit 99.1 and incorporated by reference
herein. The information in this paragraph (including Exhibit 99.1) shall not be
deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the "Exchange Act"), or otherwise subject to the
liabilities of that section, and is not incorporated by reference into any
filing under the Securities Act of 1933, as amended, or the Securities Act.
--------------------------------------------------------------------------------
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit
Number Description
99.1 Press Release dated January 4, 2021.
104 Cover Page Interactive File (the cover page tags are embedded within
the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
F-STAR THERAPEUTICS, INC. 
